2245. Primary Central Nervous System Lymphoma in patients with HIV and non-HIV: Should We Treat Them Differently?
Session: Poster Abstract Session: HIV: Malignancy
Saturday, October 6, 2018
Room: S Poster Hall
Posters
  • ID week 2018_poster.PCNSL.pdf (1.0 MB)
  • Background:

    Primary central nervous system lymphoma (PCNSL) is a rare type of non-Hodgkin lymphoma, mostly diffuse large B-cell type. In patients living with HIV (PLWH), PCNSL is associated with Epstein-Barr virus. The optimal diagnostic and prognostic tools, and treatment are yet to be defined. PLWH are typically excluded from prospective studies. The management of PCNSL is adopted from immunocompetent patients.

    Methods:

    We retrospectively reviewed 122 PCNSL cases presenting to MD Anderson Cancer Center from 2000-2016 (n=84) and Ben-Taub Hospital from 2012-2016 (n=38) to evaluate and compare the clinical characteristics, management, and clinical outcomes in patients with or without HIV infection.

    Results:

    Among 122 PCNSL cases, 21% had positive HIV test, of those, 89% had CD4 < 200 and 77% were not on antiretrovirals and not virally suppressed. PLWH were significantly younger (37 vs. 62 yrs. P<0.01), and more likely to be African-Americans (61% vs. 7%; p<0.01) and males (73% vs. 50%; p=0.04) than non-HIV patients. There were no differences in presenting symptoms, ocular involvement, B-symptoms, and deep brain involvement. PLWH were more likely to have multiple brain lesions (69% vs. 44%, p=0.02). Immunohistochemistry prognostic markers and the International Extranodal Lymphoma Study Group (IELSG) prognostic score were not different between HIV and non-HIV patients. Nevertheless, treatment strategies varied significantly. PLWH were more likely to receive whole brain radiation therapy as sole treatment (65% vs. 4%) and palliative care (12% vs. 2%), and less likely to receive chemotherapy (23% vs. 94%) (p<0.01). Also, 13% of the patients (all non-HIV) underwent autologous stem cell transplant. Most PLWH (88%) started antiretroviral therapy after diagnosis. Higher IELSG score was an independent predictor of mortality in multivariate regression analysis. The 2-year survival did not differ between PLWH and non-HIV patients [46% (30% - 72%) versus 61% (52% - 72%) (p=0.12)].

    Conclusion:

    Variation in the treatment of PCNSL between HIV and non-HIV patients is not fully explained by baseline characteristics and prognostic factors. More efforts are needed to identify causes underlying these disparities and ways to alleviate them.

    Dima Dandachi, M.D.1, Quinn Ostrom, M.P.H, Ph.D.2, Insun Chong, M.D.2, Melissa Bondy, Ph.D.2, Jose Serpa, MD, MS3, Rivka Colen, M.D.4 and Fanny Morón, M.D.5, (1)Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX, (2)Baylor College of Medicine, Houston, TX, (3)Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, TX, (4)Department of Diagnostic Radiology, Division of Diagnostic Imaging, The University of Texas, MD Anderson Cancer Center, Houston, TX, (5)Department of Radiology, Baylor College of Medicine, Houston, TX

    Disclosures:

    D. Dandachi, None

    Q. Ostrom, None

    I. Chong, None

    M. Bondy, None

    J. Serpa, None

    R. Colen, None

    F. Morón, None

    See more of: HIV: Malignancy
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.